Skip to content

Aurinia Pharmaceuticals

US · AUPH #2749 by market cap Listed 1970
14.70 -0.19 -1.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
A-
Momentum strategy signal
Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Mixed
1
■ Upgrades■ Downgrades
  • 1 upgrade vs 0 downgrades among tracked analyst rating changes.
  • Most recent: Bloom Burton moved from Hold to Buy on 2026-08-20.

Analyst consensus 3 analysts

Buy
Avg price target 19.00 +29.3%
Price target rangecurrent 14.70
Low18.00
Avg19.00
High21.00
Buy 67% Hold 33% Sell 0%
Recent ratings (20)
DateFirmAnalystRatingTarget
2026-11-02 Bloom Burton -- Buy 21.00
2026-10-30 RBC Capital -- Hold 18.00
2026-10-21 TD Cowen -- Buy 18.00
2026-08-20 Bloom Burton -- Buy 21.00
2026-08-19 TD Cowen -- Buy 17.00
2026-08-06 TD Cowen -- Buy 17.00
2026-07-20 TD Cowen -- Buy 17.00
2026-07-06 TD Cowen -- Buy 17.00
2026-05-07 TD Cowen -- Buy 17.00
2026-03-31 Bloom Burton -- Hold 15.00
2026-03-30 TD Cowen -- Buy 17.00
2026-02-27 Bloom Burton -- Hold 15.00
2026-02-27 H.C. Wainwright -- Buy 17.00
2026-02-27 RBC Capital -- Hold 15.00
2026-02-26 TD Cowen -- Buy 17.00
2025-12-03 Leerink Partners -- Hold 16.00
2025-11-07 Jefferies -- Buy 21.00
2025-11-05 H.C. Wainwright -- Buy 17.00
2025-11-04 TD Cowen -- Buy 17.00
2025-11-04 RBC Capital -- Hold 15.00

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-08-20 Bloom Burton Hold → Buy 21.00

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2025/Q4 2026-02-26 -- ±17.50% -3.19% (in line)
2025/Q3 2025-11-04 -- ±12.70% +8.35% (in line)
2025/Q2 2025-07-31 -- ±13.44% +2.15% (in line)
2025/Q1 2025-05-12 -- ±15.99% +1.50% (in line)
2024/Q4 2025-02-27 -- ±18.36% -5.03% (in line)
2024/Q3 2024-11-07 -- ±14.32% +10.90% (in line)
2024/Q2 2024-08-01 -- ±16.22% -4.59% (in line)
2024/Q1 2024-05-02 -- ±18.21% -0.58% (in line)
2023/Q4 2024-02-15 -- ±14.64% -24.47% (beat)
2023/Q3 2023-11-02 -- ±23.14% +10.52% (in line)
2023/Q2 2023-08-03 -- ±25.02% +4.24% (in line)
2023/Q1 2023-05-04 -- ±20.50% -2.99% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Aurinia Pharmaceuticals discussion 0 comments

Add a comment